[go: up one dir, main page]

WO2000023469A2 - Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments - Google Patents

Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments

Info

Publication number
WO2000023469A2
WO2000023469A2 PCT/US1999/023839 US9923839W WO0023469A2 WO 2000023469 A2 WO2000023469 A2 WO 2000023469A2 US 9923839 W US9923839 W US 9923839W WO 0023469 A2 WO0023469 A2 WO 0023469A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
igf
insulin
growth factor
igfbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/023839
Other languages
English (en)
Other versions
WO2000023469A3 (fr
Inventor
Steven Alan Rosenzweig
Mark James Horney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Priority to AU65154/99A priority Critical patent/AU6515499A/en
Publication of WO2000023469A2 publication Critical patent/WO2000023469A2/fr
Publication of WO2000023469A3 publication Critical patent/WO2000023469A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Definitions

  • Figure 4 shows the primary structures of IGFBPs 1-6. Spatially conserved cysteine residues are shown in gray. The underlined sequence indicates the epitope peptide used to generate anti-IGFBP-2 antibodies. Sequences were aligned using the Pileup component of the Wisconsin Package version 9.0 (Genetics Computer Group (GCG), Madison, Wisconsin).
  • variations in the amino acid sequence may arise naturally as allelic variations (e.g., due to genetic polymorphism) or may be produced by human intervention (e.g., by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants.
  • minor changes in amino acid sequence are generally preferred, such as conservative amino acid replacements, small internal deletions or insertions, and additions or deletions at the ends of the molecules.
  • Substitutions may be designed based on, for example, the model of Dayhoff, et al, 1978. These modifications can result in changes in the amino acid sequence, provide silent mutations, modify a restriction site, or provide other specific mutations.
  • ERGPLEHLYSLHIPN SEQ ID NO: 106
  • ERGPLEHLYSLHIP SEQ ID NO: 107
  • ERGPLEHLYSLHI SEQ ID NO.108
  • ERGPLEHLYSLH SEQ ID NO: 109
  • the intrasequence disulfide bond can be between the cysteine residues corresponding to residues 249 and 270 of IGFBP-2 or between the cysteine residues corresponding to residues 236 and 247 of IGFBP-2.
  • the reduction will be 100%, 99%, 98%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%.
  • the fragment of IGF in the present invention can comprise the amino acid sequence of GPETLCG (SEQ ID NO:80) or AYRPSETLCG (SEQ ID NO:81), which are the N-termini of IGF-1 and IGF-2, respectively.
  • the IGF fragment of the claimed invention can further comprise the amino acid sequence of SEQ ID NO: 80 or SEQ ID NO: 81 linked to the amino acid sequence FRS (SEQ ID NO:82) by a disulfide bond.
  • the lyophilized reaction mixture was dissolved in 0.5 M acetic acid and 10 ⁇ l of trifluoroacetic acid (TFA) and chromatographed on a C18 column equilibrated in 0.1% TF A 24% acetonitrile at a flow rate of 1 ml/min. After 20 min a linear gradient from 24-60% acetonitrile was developed over 60 min to elute IGF-1 and the reaction products. In addition to unreacted IGF-1 (peak 1), 3 major products are obtained. Analysis of these peaks by acidic polyacrylamide gel electrophoresis in 8 M urea has revealed that all three derivatized IGF- Is are monosubstituted, thus exhibiting the loss of 1 net positive charge.
  • TFA trifluoroacetic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention se rapporte aux parties de peptides de la protéine IGFBP (protéine de fixation du facteur IGF) et de peptides du facteur IGF (facteur de croissance proche de l'insuline) qui entrent dans la fixation IGF-IGFBP. Par conséquent, la présente invention propose un domaine de fixation d'IGF isolé d'une protéine IGFBP ou des modifications de ce domaine, qui fixe l'IGF avec au moins approximativement la même affinité de liaison que la protéine IGFBP pleine longueur. Cette invention concerne également un antagoniste d'IGF qui réduit la fixation de l'IGF à un récepteur d'IGF. Sont en outre décrits un fragment du facteur IGF ou une modification de ce fragment, qui se fixe à un domaine de fixation de l'IGFBP, un complexe protéiné contenant le domaine de fixation d'IGF de la protéine IGFBP de cette invention, ainsi que des procédés servant à traiter un sujet souffrant de cancer ou à prévenir le cancer chez un sujet, à traiter un sujet souffrant d'une complication diabétique exacerbée par IGF et à prévenir toute complication diabétique exacerbée par l'IGF et consistant à administrer à ce sujet l'antagoniste d'IGF. Cette invention propose en outre un procédé servant à traiter un sujet souffrant d'une lésion ischémique ou à prévenir une lésion ischémique chez un sujet et consistant à administrer à ce sujet le fragment d'IGF ou l'antagoniste d'IGFBP de cette invention.
PCT/US1999/023839 1998-10-16 1999-10-14 Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments Ceased WO2000023469A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65154/99A AU6515499A (en) 1998-10-16 1999-10-14 Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10452898P 1998-10-16 1998-10-16
US60/104,528 1998-10-16

Publications (2)

Publication Number Publication Date
WO2000023469A2 true WO2000023469A2 (fr) 2000-04-27
WO2000023469A3 WO2000023469A3 (fr) 2000-08-24

Family

ID=22300974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023839 Ceased WO2000023469A2 (fr) 1998-10-16 1999-10-14 Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments

Country Status (2)

Country Link
AU (1) AU6515499A (fr)
WO (1) WO2000023469A2 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251865B1 (en) 1997-04-04 2001-06-26 Genentech, Inc. Insulin-like growth factor agonist molecules
WO2002012493A1 (fr) * 2000-06-14 2002-02-14 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine de liaison 11.88 du facteur de croissance de type insuline, et polynucleotide codant ce polypeptide
WO2002012301A1 (fr) * 2000-06-14 2002-02-14 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine de liaison 16.17 du facteur de croissance de type insuline, et polynucleotide codant ce polypeptide
WO2002024219A1 (fr) 2000-09-22 2002-03-28 Queensland University Of Technology Complexe du facteur de croissance
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6506874B1 (en) 1999-01-06 2003-01-14 Genentech, Inc. IGF-I variants
WO2002098914A3 (fr) * 2001-06-07 2003-12-11 Hoffmann La Roche Mutants de proteines de liaison du facteur de croissance insulinomimetique (igf) et methodes de production d'antagonistes
WO2004033481A3 (fr) * 2002-10-04 2004-12-16 Bioexpertise Llc Peptide ou petite molecule derives d'une proteine de liaison a l'igf
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
WO2006034832A3 (fr) * 2004-09-27 2006-06-22 Univ Muenchen L Maximilians Utilisation de igfbp-2 dans des maladies de senescence et pour le maintien de fonctions d'organes
US7071300B2 (en) 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US7084240B2 (en) 2001-02-09 2006-08-01 Genentech, Inc. Crystallization of IGF-1
WO2006069765A3 (fr) * 2004-12-27 2006-08-31 Geneprot Inc Especes de polypeptides secretes impliquees dans la sclerose en plaques
US7192738B2 (en) 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US7423017B2 (en) 1997-04-04 2008-09-09 Genentech, Inc. Method for treating cartilage disorders
WO2008086813A3 (fr) * 2007-01-19 2008-12-04 Uinv Kobenhavns Peptides dérivés de protéines de la superfamille de l'insuline
WO2009019254A1 (fr) * 2007-08-03 2009-02-12 Pharis Biotec Gmbh Fragments c terminaux de igfbp-2 et leurs utilisations
US20100016226A1 (en) * 2008-06-13 2010-01-21 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2010099139A2 (fr) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Thérapie anti-cancer combinée
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
EP2381774A4 (fr) * 2008-12-23 2012-07-18 Salk Inst For Biological Studi Procédé de traitement de maladie neurodégénérative
EP2352514A4 (fr) * 2008-10-29 2012-07-25 Univ Rockefeller Procédés et kits pour traiter une maladie par administration de protéine 2 de liaison de facteur de croissance insulinomimétique
EP2462945A3 (fr) * 2006-08-16 2012-09-05 National Research Council of Canada Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
WO2013151688A1 (fr) * 2012-04-06 2013-10-10 Georgia Regents University Procédés et compositions pour utiliser la protéine de liaison au facteur de croissance insulinomimétique 6 dans le traitement et le diagnostic du diabète
EP2763687A4 (fr) * 2010-07-06 2015-05-20 Biocure Pharma Llc Procédés et compositions pour le traitement d'un syndrome métabolique, de troubles respiratoires obstructifs, du cancer et de maladies associées
EP2970387A4 (fr) * 2013-03-12 2016-07-27 Univ North Carolina Composés et méthodes destinés à traiter l'obésité et à contrôler le poids
US9550821B2 (en) 2011-12-15 2017-01-24 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
CN110248672A (zh) * 2017-02-06 2019-09-17 中央研究院 重组蛋白及其用途
WO2020256150A1 (fr) * 2019-06-21 2020-12-24 滋 天野 Peptide perméable aux cellules
WO2021011283A1 (fr) * 2019-07-12 2021-01-21 Northwestern University Fragments peptidiques bioactifs de protéine de liaison au facteur de croissance de type insuline
WO2022191868A1 (fr) * 2020-03-26 2022-09-15 Desmond Mascarenhas Modulation de lignée cellulaire chez les mammifères par des immodulines synthétiques
GB2620502A (en) * 2021-03-09 2024-01-10 Mascarenhas Desmond Modulation of mammalian cell lineage by synthetic immodulins

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233155T2 (de) * 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
AU6626794A (en) * 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689751B1 (en) 1997-04-04 2004-02-10 Genentech, Inc. Insulin-like growth factor agonist molecules
US6693078B1 (en) 1997-04-04 2004-02-17 Genentech, Inc. Insulin-like growth factor agonist molecules
US6251865B1 (en) 1997-04-04 2001-06-26 Genentech, Inc. Insulin-like growth factor agonist molecules
US7423017B2 (en) 1997-04-04 2008-09-09 Genentech, Inc. Method for treating cartilage disorders
US6949349B1 (en) 1997-04-04 2005-09-27 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US7947650B2 (en) 1997-04-04 2011-05-24 Genentech, Inc. Article of manufacture
US6750321B1 (en) 1997-04-04 2004-06-15 Genentech, Inc. Insulin-like growth factor agonist molecules
US6608031B1 (en) 1997-04-04 2003-08-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6693079B1 (en) 1997-04-04 2004-02-17 Genentech, Inc. Insulin-like growth factor agonist molecules
US6620789B1 (en) 1997-04-04 2003-09-16 Genentech, Inc. Insulin-like growth factor agonist molecules
US6632794B1 (en) 1997-04-04 2003-10-14 Genentech, Inc. Insulin-like growth factor agonist molecules
US6635619B1 (en) 1997-04-04 2003-10-21 Genentech, Inc. Insulin-like growth factor agonist molecules
US6645775B1 (en) 1997-04-04 2003-11-11 Genentech, Inc. Insulin-like growth factor agonist molecules
US8110548B2 (en) 1997-04-04 2012-02-07 Genentech, Inc. Method for treating cartilage disorders
US6677305B1 (en) 1997-04-04 2004-01-13 Genentech, Inc. Insulin-like growth factor agonist molecules
US6680298B1 (en) 1997-04-04 2004-01-20 Genentech, Inc. Insulin-like growth factor agonist molecules
US6683053B1 (en) 1997-04-04 2004-01-27 Genentech, Inc. Insulin-like growth factor agonist molecules
US6743894B1 (en) 1997-04-04 2004-06-01 Genentech, Inc. Insulin-like growth factor agonist molecules
US6716586B1 (en) 1997-04-04 2004-04-06 Genentech, Inc. Insulin-like growth factor agonist molecules
US6608028B1 (en) 1997-04-04 2003-08-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6713451B1 (en) 1997-04-04 2004-03-30 Genentech, Inc. Insulin-like growth factor agonist molecules
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6509443B1 (en) 1999-01-06 2003-01-21 Genentech, Inc. IGF-I point variants
US6506874B1 (en) 1999-01-06 2003-01-14 Genentech, Inc. IGF-I variants
US7105167B2 (en) 1999-01-06 2006-09-12 Genentech, Inc. Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant
WO2002012493A1 (fr) * 2000-06-14 2002-02-14 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine de liaison 11.88 du facteur de croissance de type insuline, et polynucleotide codant ce polypeptide
WO2002012301A1 (fr) * 2000-06-14 2002-02-14 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine de liaison 16.17 du facteur de croissance de type insuline, et polynucleotide codant ce polypeptide
EP2385064A2 (fr) 2000-09-22 2011-11-09 Queensland University of Technology Agents qui séparent un complexe du facteur de croissance
WO2002024219A1 (fr) 2000-09-22 2002-03-28 Queensland University Of Technology Complexe du facteur de croissance
US7354769B2 (en) 2001-02-09 2008-04-08 Genentech, Inc. Crystallization of IGF-1
US7238658B2 (en) 2001-02-09 2007-07-03 Genentech, Inc. Crystallization of IGF-1
US7084240B2 (en) 2001-02-09 2006-08-01 Genentech, Inc. Crystallization of IGF-1
US7433788B2 (en) 2001-02-09 2008-10-07 Genentech, Inc. Crystallization of IGF-1
US7297763B2 (en) 2001-02-09 2007-11-20 Genentech, Inc. Crystallization of IGF-1
US7596455B2 (en) 2001-02-09 2009-09-29 Genentech, Inc. Crystallization of IGF-1
US7432244B2 (en) 2001-03-14 2008-10-07 Genentech, Inc. Method of inhibiting insulin-like growth factor-1 (IGF-1) by IGF-1-antagonist peptides
US7071300B2 (en) 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US7223757B2 (en) 2001-03-28 2007-05-29 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002098914A3 (fr) * 2001-06-07 2003-12-11 Hoffmann La Roche Mutants de proteines de liaison du facteur de croissance insulinomimetique (igf) et methodes de production d'antagonistes
JP2005508295A (ja) * 2001-06-07 2005-03-31 エフ．ホフマン−ラ　ロシュ　アーゲー Ｉｇｆ結合タンパク質の変異体、およびそれらのアゴニストの作製法
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
AU2002324672B2 (en) * 2001-09-18 2007-11-08 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
WO2004033481A3 (fr) * 2002-10-04 2004-12-16 Bioexpertise Llc Peptide ou petite molecule derives d'une proteine de liaison a l'igf
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US7192738B2 (en) 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
US7348154B2 (en) 2003-10-03 2008-03-25 Genentech, Inc. IGF binding proteins
US7351545B2 (en) 2003-10-03 2008-04-01 Genentech, Inc. IGF binding proteins
WO2006034832A3 (fr) * 2004-09-27 2006-06-22 Univ Muenchen L Maximilians Utilisation de igfbp-2 dans des maladies de senescence et pour le maintien de fonctions d'organes
WO2006069765A3 (fr) * 2004-12-27 2006-08-31 Geneprot Inc Especes de polypeptides secretes impliquees dans la sclerose en plaques
EP2462945A3 (fr) * 2006-08-16 2012-09-05 National Research Council of Canada Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline
WO2008086813A3 (fr) * 2007-01-19 2008-12-04 Uinv Kobenhavns Peptides dérivés de protéines de la superfamille de l'insuline
WO2009019254A1 (fr) * 2007-08-03 2009-02-12 Pharis Biotec Gmbh Fragments c terminaux de igfbp-2 et leurs utilisations
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
US20100016226A1 (en) * 2008-06-13 2010-01-21 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
US8404639B2 (en) 2008-10-29 2013-03-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
EP2352514A4 (fr) * 2008-10-29 2012-07-25 Univ Rockefeller Procédés et kits pour traiter une maladie par administration de protéine 2 de liaison de facteur de croissance insulinomimétique
EP2381774A4 (fr) * 2008-12-23 2012-07-18 Salk Inst For Biological Studi Procédé de traitement de maladie neurodégénérative
WO2010099139A2 (fr) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Thérapie anti-cancer combinée
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
EP2763687A4 (fr) * 2010-07-06 2015-05-20 Biocure Pharma Llc Procédés et compositions pour le traitement d'un syndrome métabolique, de troubles respiratoires obstructifs, du cancer et de maladies associées
US9550821B2 (en) 2011-12-15 2017-01-24 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
WO2013151688A1 (fr) * 2012-04-06 2013-10-10 Georgia Regents University Procédés et compositions pour utiliser la protéine de liaison au facteur de croissance insulinomimétique 6 dans le traitement et le diagnostic du diabète
EP2970387A4 (fr) * 2013-03-12 2016-07-27 Univ North Carolina Composés et méthodes destinés à traiter l'obésité et à contrôler le poids
EP3576767A4 (fr) * 2017-02-06 2020-12-02 Academia Sinica Protéines recombinées et leurs utilisations
CN110248672A (zh) * 2017-02-06 2019-09-17 中央研究院 重组蛋白及其用途
WO2020256150A1 (fr) * 2019-06-21 2020-12-24 滋 天野 Peptide perméable aux cellules
JPWO2020256150A1 (ja) * 2019-06-21 2021-09-13 滋 天野 細胞透過性ペプチド
US20230210940A1 (en) * 2019-06-21 2023-07-06 Shigeru Amano Cell-permeable peptide
US12472226B2 (en) * 2019-06-21 2025-11-18 Shigeru Amano Cell-permeable peptide
WO2021011283A1 (fr) * 2019-07-12 2021-01-21 Northwestern University Fragments peptidiques bioactifs de protéine de liaison au facteur de croissance de type insuline
US11859020B2 (en) 2019-07-12 2024-01-02 Northwestern University Insulin like growth factor binding protein bioactive peptide fragments
US12421280B2 (en) 2019-07-12 2025-09-23 Northwestern University Insulin like growth factor binding protein bioactive peptide fragments
WO2022191868A1 (fr) * 2020-03-26 2022-09-15 Desmond Mascarenhas Modulation de lignée cellulaire chez les mammifères par des immodulines synthétiques
GB2620502A (en) * 2021-03-09 2024-01-10 Mascarenhas Desmond Modulation of mammalian cell lineage by synthetic immodulins

Also Published As

Publication number Publication date
AU6515499A (en) 2000-05-08
WO2000023469A3 (fr) 2000-08-24

Similar Documents

Publication Publication Date Title
WO2000023469A2 (fr) Fragments du facteur de croissance proche de l'insuline et de la proteine de fixation du facteur de croissance proche de l'insuline, et utilisations de ces fragments
US8110548B2 (en) Method for treating cartilage disorders
EP1141015B1 (fr) Variants mutants du facteur de croissance i semblable a l'insuline (igf)
EP1435986B1 (fr) Peptide derive de proteines de liaison de l'igf
EP1141014B1 (fr) Variant mutant du facteur de croissance insulinomimetique (igf) de type i
AU2002248609B2 (en) IGF antagonist peptides
EP1251137A2 (fr) Utilisation d'agonistes peptidiques du facteur de croissance analogue à l'insuline
AU2002324672A1 (en) IGF-binding protein-derived peptide or small molecule
AU2002248609A1 (en) IGF antagonist peptides
CA2501057A1 (fr) Peptide ou petite molecule derives d'une proteine de liaison a l'igf
EP1148129B1 (fr) Modification de betacelluline
EP2152742B1 (fr) Protéines de liaison à l'IGF-1R et antagonistes
US20230085176A1 (en) Peptide-based inhibitors of growth hormone action and methods of use thereof
AU2003236454B2 (en) Insulin-like growth factor (IGF) I mutant variants
HK1050321B (en) Treatment of cartilage disorders
EP1506972A1 (fr) Variants mutants du facteur de croissance insulinomimétique (IGF) de type I
HK1062923B (en) Igf-binding protein-derived peptide
AU2007202546A1 (en) IGF antagonist peptides

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 65154

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase